Dou Xiarui
senior partner/partner/agent/lawyer
douxr@ipsunny.com
macromolecule、chemistry、micromolecule
• PhD in Pharmacy from Beijing University of Traditional Chinese Medicine
• Master's degree in Law from Peking University Law School
• "2013 China's Outstanding Intellectual Property Manager"/"2016 exemplary individual in China's Enterprise Intellectual Property Work"/Expert in the Expert Database of the Chinese Society of Traditional Chinese Medicine/Expert in the Beijing Intellectual Property Expert Database
• Currently serving as Executive Director of the Intellectual Property Committee of the Chinese Association of Traditional Chinese Medicine, Member of the Pharmaceutical Professional Committee of the China Patent Protection Association, and Vice Chairman of the Yangtze River Delta Biomedical Intellectual Property Alliance
• Engaged in intellectual property work for nearly 20 years, with over ten years of experience in large pharmaceutical companies (listed companies) such as Tasly Pharmaceutical Group, Yabao Pharmaceutical Group, Yangzijiang Pharmaceutical Group, and Chengdu Beite Pharmaceutical, serving as senior legal advisor, legal director, or intellectual property director
• Proficient in patent certification, layout protection, design avoidance FTO、 Patent invalidation litigation, due diligence in transactions, etc., especially familiar with the unique connection between patent protection and administrative protection in the pharmaceutical field, drug patent linkage system, and risk control in drug technology transactions
• Hosted invalidation and/or confirmation litigation cases related to alogliptin benzoate, propranolol, dexmedetomidine, voxetine, linagliptin crystal form, idoxaban complex, and alamoxa. Multiple cases were selected/awarded as one of the top ten cases of invalidation in the 2019 State Intellectual Property Administration review, the top ten cases of invalidation in the 2020 State Intellectual Property Administration review, and typical cases of specialized intellectual property trials in Beijing courts over the past thirty years
• Independently published professional articles such as "On the Reform of Dual Regulation and Linkage System in Drug Protection in China" and co authored nearly ten books as the main editor, including "Intellectual Property Management of Chinese Pharmaceutical Enterprises"
• Master's degree in Law from Peking University Law School
• "2013 China's Outstanding Intellectual Property Manager"/"2016 exemplary individual in China's Enterprise Intellectual Property Work"/Expert in the Expert Database of the Chinese Society of Traditional Chinese Medicine/Expert in the Beijing Intellectual Property Expert Database
• Currently serving as Executive Director of the Intellectual Property Committee of the Chinese Association of Traditional Chinese Medicine, Member of the Pharmaceutical Professional Committee of the China Patent Protection Association, and Vice Chairman of the Yangtze River Delta Biomedical Intellectual Property Alliance
• Engaged in intellectual property work for nearly 20 years, with over ten years of experience in large pharmaceutical companies (listed companies) such as Tasly Pharmaceutical Group, Yabao Pharmaceutical Group, Yangzijiang Pharmaceutical Group, and Chengdu Beite Pharmaceutical, serving as senior legal advisor, legal director, or intellectual property director
• Proficient in patent certification, layout protection, design avoidance FTO、 Patent invalidation litigation, due diligence in transactions, etc., especially familiar with the unique connection between patent protection and administrative protection in the pharmaceutical field, drug patent linkage system, and risk control in drug technology transactions
• Hosted invalidation and/or confirmation litigation cases related to alogliptin benzoate, propranolol, dexmedetomidine, voxetine, linagliptin crystal form, idoxaban complex, and alamoxa. Multiple cases were selected/awarded as one of the top ten cases of invalidation in the 2019 State Intellectual Property Administration review, the top ten cases of invalidation in the 2020 State Intellectual Property Administration review, and typical cases of specialized intellectual property trials in Beijing courts over the past thirty years
• Independently published professional articles such as "On the Reform of Dual Regulation and Linkage System in Drug Protection in China" and co authored nearly ten books as the main editor, including "Intellectual Property Management of Chinese Pharmaceutical Enterprises"